EU/3/18/2125

About

On 11 January 2019, orphan designation (EU/3/18/2125) was granted by the European Commission to Isabelle Ramirez, Germany, for benserazide hydrochloride for treatment of sickle cell disease.

Key facts

Active substance
Benserazide hydrochloride
Disease / condition
The treatment of sickle cell disease
Date of first decision
11/01/2019
Outcome
Positive
EU designation number
EU/3/18/2125

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Isabelle Ramirez
Steinstrasse 54
D-81667 Munich
Germany
Tel. + 49 89 67973000
Fax + 49 89 67973272
E-mail: info@zerimar.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating